Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 78 tables and 119 figures, this 215-page report “Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Region: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire global biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify the global biopharmaceuticals market in every aspect of the classification from perspectives of Product Type, Testing Service, Raw Material, Classification, Therapeutic Area, and Region.

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Monoclonal Antibodies


o Anti-cancer Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies

  • Recombinant Growth Factors


o Erythropoietin
o Granulocyte Colony Stimulating Factor

  • Purified Proteins


o Leukemia Inhibitory Factor (LIF)
o P53 Protein
o P38 Protein
o Other Purified Proteins

  • Recombinant Proteins


o Serum Albumin
o Amyloid Protein
o Defensin
o Transferrin

  • Recombinant Hormones


o Recombinant Human Growth Hormones
o Recombinant Insulin
o Other Recombinant Hormones

  • Vaccines


o Recombinant Vaccines
? Cancer Vaccines
? Malaria Vaccines
? Ebola Vaccines
? Hepatitis Vaccines
? Tetanus Vaccines
? Diphtheria Vaccines
? Cholera Vaccines
? Other Recombinant Vaccines
o Conventional Vaccines
? Polio Vaccines
? Pox Vaccines
? Other Conventional Vaccines

  • Recombinant Enzymes


o Enterokinase
o Cyclase
o Caspase
o Cathepsin

  • Cell and Gene Therapies


o Allogenic Products
o Autologous Products
o Acellular Products

  • Synthetic Immunomodulators
  • Other Product Types


o Blood Factors
o Other Products

Based on Testing Service, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Laboratory Testing
  • Custom Testing/Customer Proprietary Testing
  • Compendial and Multi Compendial Laboratory Testing



By Raw Material, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Formulation Excipients
  • Active Pharmaceutical Ingredients (API)
  • Other Materials



By Classification, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Innovative Biopharmaceuticals
  • Biogenerics and Biosimilars



By Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Therapeutic Areas



Geographically, the following regions together with the listed national/local markets are fully investigated:

  • North America (U.S., Canada, and Mexico)
  • Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
  • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
  • South America (Brazil, Chile, Argentina, Rest of South America)
  • MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)


For each region and country, detailed analysis and annual revenue ($ mn) are available for 2023-2033. The breakdown of all regional markets by country and the breakdown of each national market by Product Type and Therapeutic Area over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)